We believe that better care for people with serious and disabling illnesses requires better data.

Indeed, all too often, caregivers lack precise information on patients’ symptoms and feelings. By designing digital biomarkers, which continuously measure disease evolution in real life, we are paving a new path to progress.

A new path to progress where each person can be an actor in their own health.

A new path to progress for healthcare professionals to offer more individualized and more efficient care.

A new path to progress to accelerate the development of treatments work environment, reduce the societal and economic impact of diseases.

We want to be useful today to the greatest number of people. For them, as a pioneer in digital biomarkers, we set ourselves ambitious goals, which we pursue relentlessly. Our obsession: to get results quickly, because our scientific and technological progress only make sense if they are shared widely and rapidly.

We do this without compromising on the security and confidentiality of the health data entrusted to us.

Every day, we combine our expertise with our agility to create an inclusive environment, fostering innovation and thus passionately support our mission to serve patients.

What is new ?

A new governance for Ad Scientiam

Matthieu Lamy appointed President of Ad Scientiam to lead the company's development

Read the article

MSCopilot® : new clinical results

New clinical results confirm central role of digital biomarkers in the monitoring of patients with multiple sclerosis

Read the article

2nd phase of study on depressive disorders

Ad Scientiam launches the 2nd phase of its study on depressive disorders: 60 new volunteers suffering from depressive disorders will be recruited

Read the article
They trust us
Our solutions

Ad Scientiam designs, validates and implements digital biomarkers that continuously measure disease progression in real life.

These are derived from data continuously collected via a digital tool, such as the patient's smartphone for example, and transformed by proprietary algorithms.

The MSCopilot® example

The 1st software medical device for multiple sclerosis self-assessment

Launched in 2018, MSCopilot® is the first and only CE-marked software medical device for the real-life self-assessment of Multiple Sclerosis (MS) patients.

Using patients' smartphones, MSCopilot® captures more than 350 digital biomarkers on physiological and behavioral characteristics to objectify MS-related symptoms.

Come and innovate with us!

Join our team!

Our team is growing and is always looking for the best talents to accelerate its development:

If you want to participate in the adventure and help us build the medicine of tomorrow, come and find out about our job offers and send us your application!

You are a Healthcare Professional ?

You want to use one of our solutions to monitor your patients continuously and in real life.

You have a research project ?

You are looking to set up a research project (therapeutic trial, epidemiological study, evaluation study, etc.).

MSCopilot®: New clinical results confirm central role of digital biomarkers in the monitoring of patients with multiple sclerosis Our news
en_USEnglish